-
A 51-year-old man, a foreman for a local construction business, presented to the emergency department with progressive lower back pain of 2 weeks duration and shortness of breath. Initially mild, the pain had become incapacitating within the prior 48 hours.
-
Calcium supplements and MI; birth control pills and VTE; ACE inhibitors and breast cancer risk; spending on pharmaceuticals; and FDA actions.
-
In the vulvar vestibulitis clinical trial conducted at the University of Rochester between 2002 and 2007, patients with vulvar vestibulitis syndrome (localized provoked vulvodynia) were enrolled in a 12-week randomized, placebo-controlled treatment trial.
-
-
Over the years, different tocolytics have been in vogue, only to be discarded later because meta-analyses showed that the agent simply did not work. This month's review will focus on nifedipine, a medication that has been in and out of favor for more than 20 years.
-
This publication is an update on osteoporosis screening from the 2002 U.S. Preventive Services Task Force (USPSTF) recommendation.
-
Although the annual incidence of all gynecological malignancies remains between 75,000 and 80,000, a far greater number of women with this history are survivors.
-
In this issue: Calcium supplements and MI; birth control pills and VTE; ACE inhibitors and breast cancer risk; spending on pharmaceuticals; and FDA actions.
-
When HIV is not diagnosed until women go into labor, their infants usually are treated soon after birth with the antiretroviral drug zidovudine to prevent infant infection.
-
Amphora, under development by Evofem of San Diego, is a bioadhesive acid-buffering gel that coats the vaginal wall and cervix. Amphora helps maintain a woman's natural pH level between 3.8 and 4.2.
